Advertisement

Topics

Multiple Myeloma Research Foundation Company Profile

06:16 EDT 22nd October 2017 | BioPortfolio

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $140 million since its inception to fund nearly 120 laboratories worldwide. An outstanding 93% of funds raised go toward research and related programming. The MMRF has supported 40 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 24 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC). For more information about the MMRF, please visit www.themmrf.org.


News Articles [1347 Associated News Articles listed on BioPortfolio]

Multiple Myeloma Research Foundation to launch “Answer Fund”

The Multiple Myeloma Research Foundation (MMRF) announced that it is investing $5 million over the next three years to launch “The MMRF Answer Fund,” a multifaceted effort to address important que...

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Professor Joy Ho (Royal Prince Alfred Hospital, Sydney, Australia) and Professor Je-Jung Lee (Chairman, Korean Multiple Myeloma Working Party) discuss current treatment paradigms in newly diagnosed mu...

Novel Quadruplet Therapy Shows Promise in Multiple Myeloma

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

Multiple Myeloma Research Foundation (MMRF) Announces $5 Million Investment To Launch “Answer Fund”

Fund will harness MMRF CoMMpass Study data to address critical questions facing the myeloma community The Multiple Myeloma Research Foundation (MMRF) announced today...

Current and future prospects in treating multiple myeloma

Dr Giralt speaks with ecancer at the Best of ASCO meeting in Miami to discuss current and future prospect in treating multiple myeloma. He outlines the changing understanding of myeloma as a family o...

FDA halts two multiple myeloma Keytruda trials

Based on data from two recently halted clinical trials, the FDA is issuing this statement to inform the public, healthcare professionals and oncology clinical investigators about the risks associated ...

Multiple Myeloma Patients and Supporters Embark on Cross-Country Journey to Raise Awareness and ...

At www.RoadToVictories.com, visitors can watch inspiring stories from the cyclists, learn more about how to navigate living with multiple myeloma, and sign up for Read more...

The Binding Site Fosters Discussion of Common, but Often Missed, Symptoms of Multiple Myeloma

Yorba Linda, Ca (PRWEB) August 28, 2017 Primary care physicians see more than 50 percent of myeloma patients with early symptoms, an...

PubMed Articles [2525 Associated PubMed Articles listed on BioPortfolio]

Glomerulonephritis as a Type of Kidney Injury in Multiple Myeloma: a Report of 2 Cases.

Renal involvement in multiple myeloma has multiple etiologies. Glomerulonephritis rarely occurs in multiple myeloma and numerous case reports in the literature explain their correlation. We report 2 c...

Clinical features of multiple myeloma patients with isolated extramedullary relapse.

This study sought to analyze the clinical features and prognosis of multiple myeloma with isolated extramedullary relapse and with the absence of systemic progression. The clinical features and outcom...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal dam...

Targeting autophagy in multiple myeloma.

Autophagy plays an important role in plasma cell ontogeny and in the pathophysiology of multiple myeloma. Autophagy is usually considered a pro-survival mechanism, and cooperates with the ubiquitin pr...

Correlation of Th17 Cells and IL-17 Level in Multiple Myeloma Patients with Pathogenesis of Multiple Myeloma.

To explore the correlation of Th17 cell rate and IL-17 level with pathogenetis of multiple myeloma(MM).

Clinical Trials [4225 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and fe...

Companies [3099 Associated Companies listed on BioPortfolio]

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

GNS Healthcare and The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathyâ€...

GNS Healthcare (GNS) and Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathyâ€...

More Information about "Multiple Myeloma Research Foundation" on BioPortfolio

We have published hundreds of Multiple Myeloma Research Foundation news stories on BioPortfolio along with dozens of Multiple Myeloma Research Foundation Clinical Trials and PubMed Articles about Multiple Myeloma Research Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Multiple Myeloma Research Foundation Companies in our database. You can also find out about relevant Multiple Myeloma Research Foundation Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record